{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:47Z","timestamp":1792801727643,"version":"4.5.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, And Blood Institute","doi-asserted-by":"crossref","award":["R01HL131517"],"award-info":[{"award-number":["R01HL131517"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, And Blood Institute","doi-asserted-by":"crossref","award":["R01HL136389"],"award-info":[{"award-number":["R01HL136389"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.phrs.2019.104521","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:18:28Z","timestamp":1574165908000},"page":"104521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"special_numbering":"C","title":["The role of amiodarone in contemporary management of complex cardiac arrhythmias"],"prefix":"10.1016","volume":"151","author":[{"given":"Neboj\u0161a","family":"Mujovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Marinkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana S.","family":"Potpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0005","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FJC.0b013e31818914b6","article-title":"Amiodarone as paradigm for developing new drugs for atrial fibrillation","volume":"52","author":"Singh","year":"2008","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0010","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11886-006-0074-2","article-title":"Amiodarone: a multifaceted antiarrhythmic drug","volume":"8","author":"Singh","year":"2006","journal-title":"Curr. Cardiol. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1476-5381.1970.tb09891.x","article-title":"The effect of amiodarone, a new anti-anginal drug, on cardiac muscle","volume":"39","author":"Singh","year":"1970","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/CIRCULATIONAHA.111.019927","article-title":"Antiarrhythmic drug therapy for atrial fibrillation","volume":"125","author":"Zimetbaum","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0025","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1540-8159.1984.tb04897.x","article-title":"Is amiodarone an ideal antiarrhythmic drug?","volume":"7","author":"Rosenbaum","year":"1984","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/europace\/eux373","volume":"20","author":"Dan","year":"2018","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0035","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.amjcard.2014.11.005","article-title":"Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease","volume":"115","author":"Allen LaPointe","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2019.104521_bib0040","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.298.11.1312","article-title":"Prescribing amiodarone: an evidence-based review of clinical indications","volume":"298","author":"Vassallo","year":"2007","journal-title":"JAMA"},{"issue":"9a","key":"10.1016\/j.phrs.2019.104521_bib0045","doi-asserted-by":"crossref","first-page":"20r","DOI":"10.1016\/S0002-9149(99)00698-0","article-title":"Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent","volume":"84","author":"Kodama","year":"1999","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0008-6363(97)00114-4","article-title":"Cellular electropharmacology of amiodarone","volume":"35","author":"Kodama","year":"1997","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0055","first-page":"719","article-title":"Acute and chronic effects of amiodarone on mammalian ventricular cells","volume":"37","author":"Kodama","year":"1996","journal-title":"Heart J."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0022-3565(24)38118-2","article-title":"Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes","volume":"289","author":"Bosch","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0065","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0735-1097(98)00330-1","article-title":"Amiodarone reduces transmural heterogeneity of repolarization in the human heart","volume":"32","author":"Drouin","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0008-6363(99)00232-1","article-title":"Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol","volume":"44","author":"Merot","year":"1999","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0075","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1161\/01.CIR.90.4.1811","article-title":"The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans","volume":"90","author":"Sager","year":"1994","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.phrs.2019.104521_bib0080","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/europace\/eum196","article-title":"Comparative effects of acute vs. chronic oral amiodarone treatment during acute myocardial infarction in rats","volume":"9","author":"Kolettis","year":"2007","journal-title":"EP Europace"},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0085","doi-asserted-by":"crossref","first-page":"R543","DOI":"10.1152\/ajpregu.00608.2001","article-title":"Opposite effects of iv amiodarone on cardiovascular vagal and sympathetic efferent activities in rats","volume":"283","author":"Dias Da Silva","year":"2002","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"12","key":"10.1016\/j.phrs.2019.104521_bib0090","first-page":"1805","article-title":"Tissue distribution of amiodarone and desethylamiodarone in rats after repeated oral administration of various amiodarone dosages","volume":"35","author":"Plomp","year":"1985","journal-title":"ArzneimittelForschung"},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0735-1097(84)80103-5","article-title":"Hemodynamic effects of intravenous amiodarone","volume":"4","author":"Kosinski","year":"1984","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1067\/mcp.2000.103822","article-title":"Local venous response to N-desethylamiodarone in humans","volume":"67","author":"Grossmann","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0009-9236(98)90179-5","article-title":"Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo","volume":"64","author":"Grossman","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0002-9149(76)90148-X","article-title":"Effect of amiodarone in the Wolff-Parkinson-White syndrome","volume":"38","author":"Wellens","year":"1976","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0115","first-page":"169","article-title":"Hemodynamic profile of amiodarone during acute and long-term administration in patients with ventricular dysfunction","volume":"1","author":"Remme","year":"1990","journal-title":"Cardioscience"},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1472-8206.2004.00308.x","article-title":"Acute cardiodepressant effects induced by bolus intravenous administration of amiodarone in rabbits","volume":"19","author":"Lessa","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"38","key":"10.1016\/j.phrs.2019.104521_bib0125","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"issue":"14","key":"10.1016\/j.phrs.2019.104521_bib0130","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jacc.2017.10.053","volume":"72","author":"Al-Khatib","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7 Suppl 1","key":"10.1016\/j.phrs.2019.104521_bib0135","first-page":"I6","article-title":"Clinical pharmacokinetics of amiodarone","volume":"10","author":"Haffajee","year":"1987","journal-title":"Clin. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0140","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(87)80320-0","article-title":"Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity","volume":"9","author":"Greenberg","year":"1987","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0145","first-page":"265","article-title":"Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration","volume":"1","author":"Plomp","year":"1987","journal-title":"In Vivo"},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0150","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/j.1552-4604.1989.tb03352.x","article-title":"Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effects, dose and drug concentrations to intracellular inclusion bodies","volume":"29","author":"Somani","year":"1989","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104521_bib0155","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1067\/mcp.2000.107047","article-title":"Population pharmacokinetics of long-term oral amiodarone therapy","volume":"67","author":"Pollak","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2019.104521_bib0160","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/0002-8703(88)90010-5","article-title":"Concentration response relationships of amiodarone and desethylamiodarone","volume":"115","author":"Connolly","year":"1988","journal-title":"Am. Heart J."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.2009.03381.x","article-title":"Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity","volume":"67","author":"Lafuente-Lafuente","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0170","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s002280050388","article-title":"Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure","volume":"53","author":"Candinas","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"693","key":"10.1016\/j.phrs.2019.104521_bib0175","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/pgmj.59.693.440","article-title":"Renal elimination of amiodarone and its desethyl metabolite","volume":"59","author":"Harris","year":"1983","journal-title":"Postgrad. Med. J."},{"issue":"15","key":"10.1016\/j.phrs.2019.104521_bib0180","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJM198304143081518","article-title":"Amiodarone in patients on long-term dialysis","volume":"308","author":"Bonati","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0735-1097(92)90069-Y","article-title":"High dose oral amiodarone loading: electrophysiologic effects and clinical tolerance","volume":"19","author":"vans","year":"1992","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0002-9149(85)90305-4","article-title":"Intravenous and oral loading versus oral loading alone with amiodarone for chronic refractory ventricular arrhythmias","volume":"55","author":"Kerin","year":"1985","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0195","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/clc.4960200414","article-title":"Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety","volume":"20","author":"Lee","year":"1997","journal-title":"Clin. Cardiol."},{"issue":"24","key":"10.1016\/j.phrs.2019.104521_bib0200","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1001\/jama.1992.03480240051033","article-title":"Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter","volume":"267","author":"Gosselink","year":"1992","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0735-1097(97)00220-9","article-title":"Adverse effects of low dose amiodarone: a meta-analysis","volume":"30","author":"Vorperian","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2019.104521_bib0210","doi-asserted-by":"crossref","DOI":"10.1136\/emj.2005.033860","article-title":"Amiodarone induced thrombophlebitis","volume":"23","author":"Showkathali","year":"2006","journal-title":"Emerg. Med. J."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0215","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1440-1681.2009.05303.x","article-title":"The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period","volume":"37","author":"Cushing","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.phrs.2019.104521_bib0220","first-page":"465","article-title":"Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia","volume":"6","author":"Van Herendael","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.phrs.2019.104521_bib0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.resuscitation.2018.11.018","article-title":"European Resuscitation Council Guidelines for resuscitation: 2018 update - antiarrhythmic drugs for cardiac arrest","volume":"134","author":"Soar","year":"2019","journal-title":"Resuscitation"},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0230","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/157016108784912019","article-title":"Amiodarone hepatotoxicity","volume":"6","author":"Babatin","year":"2008","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104521_bib0235","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2165\/00002018-200326060-00004","article-title":"Potentially significant drug interactions of class III antiarrhythmic drugs","volume":"26","author":"Yamreudeewong","year":"2003","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.phrs.2019.104521_bib0240","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/00002018-200023060-00003","article-title":"Antiarrhythmic agents: drug interactions of clinical significance","volume":"23","author":"Trujillo","year":"2000","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0245","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0735-1097(84)80327-7","article-title":"Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications","volume":"4","author":"Nademanee","year":"1984","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0250","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.amjmed.2015.08.039","article-title":"Practical management guide for clinicians who treat patients with amiodarone","volume":"129","author":"Epstein","year":"2016","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0255","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ahj.2010.07.008","article-title":"Dronedarone and vitamin K antagonists: a review of drug-drug interactions","volume":"160","author":"Shirolkar","year":"2010","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0260","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0735-1097(85)80091-7","article-title":"Pharmacokinetic evaluation of the digoxin-amiodarone interaction","volume":"5","author":"Fenster","year":"1985","journal-title":"J. Am. Coll. Cardiol."},{"issue":"13","key":"10.1016\/j.phrs.2019.104521_bib0265","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in Nonvalvular Atrial Fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.phrs.2019.104521_bib0270","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euy054","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary","author":"Steffel","year":"2018","journal-title":"Europace"},{"issue":"12","key":"10.1016\/j.phrs.2019.104521_bib0275","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jacc.2018.01.044","article-title":"Rivaroxaban with and without amiodarone in renal impairment","volume":"71","author":"Cheong","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0280","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1520-037X.2005.4060.x","article-title":"Adverse events with concomitant amiodarone and statin therapy","volume":"8","author":"Alsheikh-Ali","year":"2005","journal-title":"Prev. Cardiol."},{"issue":"21","key":"10.1016\/j.phrs.2019.104521_bib0285","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-Drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the american heart association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2019.104521_bib0290","first-page":"29","article-title":"Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers","volume":"7","author":"Kawabata","year":"2015","journal-title":"Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0295","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0735-1097(02)02709-2","article-title":"Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction","volume":"41","author":"Essebag","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0300","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0735-1097(86)80234-0","article-title":"Flecainide and amiodarone interaction","volume":"7","author":"Shea","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104521_bib0305","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/clpt.1987.82","article-title":"Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide","volume":"41","author":"Windle","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0310","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2125.2000.00163.x","article-title":"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice","volume":"49","author":"Libersa","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0315","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0735-1097(02)02705-5","article-title":"Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis","volume":"41","author":"Chevalier","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0320","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archinte.163.7.777","article-title":"Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis","volume":"163","author":"Letelier","year":"2003","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0325","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacc.2010.07.046","article-title":"A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation","volume":"57","author":"Camm","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"13","key":"10.1016\/j.phrs.2019.104521_bib0330","first-page":"913","article-title":"Amiodarone to prevent recurrence of atrial fibrillation","volume":"342","author":"Roy","year":"2000","journal-title":"Canadian Trial of Atrial Fibrillation Investigators, The New England journal of medicine"},{"issue":"18","key":"10.1016\/j.phrs.2019.104521_bib0335","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa041705","article-title":"Amiodarone versus sotalol for atrial fibrillation","volume":"352","author":"Singh","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0340","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0735-1097(03)00559-X","article-title":"Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug","volume":"42","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0345","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/heart.84.3.251","article-title":"Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study","volume":"84","author":"Kochiadakis","year":"2000","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0350","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archinte.166.7.719","article-title":"Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials","volume":"166","author":"Lafuente-Lafuente","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"10.1016\/j.phrs.2019.104521_bib0355","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"issue":"8","key":"10.1016\/j.phrs.2019.104521_bib0360","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s12325-017-0590-z","article-title":"Catheter ablation of atrial fibrillation: an overview for clinicians","volume":"34","author":"Mujovic","year":"2017","journal-title":"Adv. Ther."},{"issue":"23","key":"10.1016\/j.phrs.2019.104521_bib0365","first-page":"2574","article-title":"Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT)","volume":"98","author":"Deedwania","year":"1998","journal-title":"The Department of Veterans Affairs CHF-STAT Investigators, Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2019.104521_bib0370","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/00003246-200106000-00011","article-title":"Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias","volume":"29","author":"Delle Karth","year":"2001","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.phrs.2019.104521_bib0375","author":"Boriani","year":"2018","journal-title":"Europace"},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0380","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1097\/CCM.0b013e3181a02f56","article-title":"Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation","volume":"37","author":"Siu","year":"2009","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0385","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/europace\/eun020","article-title":"Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation","volume":"10","author":"Tan","year":"2008","journal-title":"Europace"},{"issue":"9\u201310","key":"10.1016\/j.phrs.2019.104521_bib0390","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2298\/SARH1110591M","article-title":"[Long-term follow-up after catheter-ablation of atrioventricular junction and pacemaker implantation in patients with uncontrolled atrial fibrillation and heart failure]","volume":"139","author":"Mujovic","year":"2011","journal-title":"Srp. Arh. Celok. Lek."},{"issue":"12","key":"10.1016\/j.phrs.2019.104521_bib0395","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"9019","key":"10.1016\/j.phrs.2019.104521_bib0400","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","article-title":"Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol","volume":"348","author":"Waldo","year":"1996","journal-title":"Lancet (London, England)"},{"issue":"25","key":"10.1016\/j.phrs.2019.104521_bib0405","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure","volume":"358","author":"Kober","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9053","key":"10.1016\/j.phrs.2019.104521_bib0410","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(96)09145-3","article-title":"Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators","volume":"349","author":"Julian","year":"1997","journal-title":"Lancet (London, England)"},{"issue":"9053","key":"10.1016\/j.phrs.2019.104521_bib0415","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(96)08171-8","article-title":"Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators","volume":"349","author":"Cairns","year":"1997","journal-title":"Lancet (London, England)"},{"issue":"25","key":"10.1016\/j.phrs.2019.104521_bib0420","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa0708789","article-title":"Rhythm control versus rate control for atrial fibrillation and heart failure","volume":"358","author":"Roy","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0425","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0197-2456(92)90036-Y","article-title":"Congestive heart failure: survival trial of antiarrhythmic therapy (CHF STAT). The CHF STAT Investigators","volume":"13","author":"Singh","year":"1992","journal-title":"Control. Clin. Trials"},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0430","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199507133330201","article-title":"Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia","volume":"333","author":"Singh","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.phrs.2019.104521_bib0435","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.115.019406","article-title":"Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial","volume":"133","author":"Di Biase","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0440","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0445","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2298\/VSP1001048M","article-title":"[The role of the accessory pathway radiofrequency catheter ablation in the secondary prevention of the malignant tachyarrhythmias in patients with Wolff-Parkinson-White syndrome]","volume":"67","author":"Mujovic","year":"2010","journal-title":"Vojnosanit. Pregl."},{"issue":"9","key":"10.1016\/j.phrs.2019.104521_bib0450","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1540-8167.2011.02013.x","article-title":"Lethal outcome after intravenous administration of amiodarone in patient with atrial fibrillation and ventricular preexcitation","volume":"22","author":"NEBOJ\u0160A","year":"2011","journal-title":"J. Cardiovasc. Electrophysiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0455","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/europace\/euw301","volume":"19","author":"Katritsis","year":"2017","journal-title":"Europace"},{"issue":"19","key":"10.1016\/j.phrs.2019.104521_bib0460","first-page":"1496","article-title":"Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy","volume":"103","author":"Lee","year":"2017","journal-title":"Arrhythmias and sudden death"},{"issue":"19","key":"10.1016\/j.phrs.2019.104521_bib0465","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.jacc.2018.07.098","article-title":"Stroke risk stratification for atrial fibrillation patients with hypertrophic cardiomyopathy","volume":"72","author":"Jung","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0470","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/hrt.79.4.331","article-title":"Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population","volume":"79","author":"Cecchi","year":"1998","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0475","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jsha.2017.03.008","article-title":"Atrial fibrillation after cardiac surgery: Prevention and management: The Australasian experience","volume":"30","author":"Alawami","year":"2018","journal-title":"J. Saudi Heart Assoc."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0480","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.athoracsur.2006.06.032","article-title":"Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis","volume":"82","author":"Bagshaw","year":"2006","journal-title":"Ann. Thorac. Surg."},{"issue":"6","key":"10.1016\/j.phrs.2019.104521_bib0485","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.amjms.2016.08.013","article-title":"Acute amiodarone pulmonary toxicity after surgical procedures","volume":"352","author":"Teerakanok","year":"2016","journal-title":"Am. J. Med. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0490","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/S0735-1097(00)00635-5","article-title":"Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter","volume":"35","author":"Natale","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0495","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/emj.2007.051086","article-title":"Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment?","volume":"25","author":"Tomlinson","year":"2008","journal-title":"Emerg. Med. J."},{"issue":"17","key":"10.1016\/j.phrs.2019.104521_bib0500","first-page":"1329","article-title":"Randomized comparison of intravenous procainamide vs. Intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study","volume":"38","author":"Ortiz","year":"2017","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.phrs.2019.104521_bib0505","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9149(02)02707-8","article-title":"Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia","volume":"90","author":"Somberg","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0510","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/0735-1097(90)90324-I","article-title":"Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: basel Antiarrhythmic Study of Infarct Survival (BASIS)","volume":"16","author":"Burkart","year":"1990","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8921","key":"10.1016\/j.phrs.2019.104521_bib0515","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(94)91895-3","article-title":"Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)","volume":"344","author":"Doval","year":"1994","journal-title":"Lancet (London, England)"},{"issue":"26","key":"10.1016\/j.phrs.2019.104521_bib0520","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators","volume":"335","author":"Moss","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.phrs.2019.104521_bib0525","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1056\/NEJM199912163412503","article-title":"A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators","volume":"341","author":"Buxton","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.phrs.2019.104521_bib0530","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0535","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter\u2013Defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2019.104521_bib0540","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0735-1097(03)00297-3","article-title":"Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT","volume":"41","author":"Strickberger","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0545","first-page":"280","article-title":"The CASCADE Investigators","volume":"72","author":"Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study)","year":"1993","journal-title":"Am. J. Cardiol."},{"issue":"24","key":"10.1016\/j.phrs.2019.104521_bib0550","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":"Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study","volume":"21","author":"Connolly","year":"2000","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.phrs.2019.104521_bib0555","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jamainternmed.2013.428","article-title":"Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches","volume":"173","author":"Borne","year":"2013","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0560","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0565","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/europace\/euq073","article-title":"Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators","volume":"12","author":"Van Herendael","year":"2010","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0570","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0735-1097(02)02709-2","article-title":"Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction","volume":"41","author":"Essebag","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0575","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1540-8159.2006.00424.x","article-title":"Clinical study of amiodarone-associated torsade de pointes in Chinese people","volume":"29","author":"Geng","year":"2006","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"suppl_K","key":"10.1016\/j.phrs.2019.104521_bib0580","doi-asserted-by":"crossref","first-page":"K70","DOI":"10.1016\/S1520-765X(01)90009-4","article-title":"Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes","volume":"3","author":"Darp\u00f6","year":"2001","journal-title":"Eur. Heart J. Suppl."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0585","first-page":"269","article-title":"Amiodarone-induced thyroid dysfunction in clinical practice","volume":"10","author":"Ursella","year":"2006","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0590","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.100.2.149","article-title":"Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease","volume":"100","author":"Thorne","year":"1999","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0595","first-page":"421","article-title":"Amiodarone-induced thyrotoxicosis: a review","volume":"25","author":"Tsang","year":"2009","journal-title":"Can. J. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0600","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3949\/ccjm.70.7.624","article-title":"Amiodarone induced thyrotoxicosis: diagnostic and therapeutic strategies","volume":"70","author":"Cardenas","year":"2003","journal-title":"Cleve. Clin. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0605","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0885066613503278","article-title":"Amiodarone-induced thyroid dysfunction","volume":"30","author":"Danzi","year":"2015","journal-title":"J. Intensive Care Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0610","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1210\/jc.2011-2390","article-title":"Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial","volume":"97","author":"Eskes","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0615","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486957","article-title":"European thyroid association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction","volume":"7","author":"Bartalena","year":"2018","journal-title":"Eur. Thyroid J."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0620","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4037\/ccn2006.26.3.34","article-title":"Amiodarone-induced thyroid dysfunction","volume":"26","author":"Porsche","year":"2006","journal-title":"Crit. Care Nurse"},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0625","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/2042018811398516","article-title":"Management of amiodarone-related thyroid problems","volume":"2","author":"Narayana","year":"2011","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0630","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.0306-5251.2003.02055.x","article-title":"A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone","volume":"57","author":"Loke","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0635","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5858\/1999-123-0251-SICCBA","article-title":"Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature","volume":"123","author":"Chang","year":"1999","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0640","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.1840090504","article-title":"Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients","volume":"9","author":"Lewis","year":"1989","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0645","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.1840080514","article-title":"Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease","volume":"8","author":"Guigui","year":"1988","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0650","first-page":"43","article-title":"Amiodarone pulmonary toxicity","volume":"16","author":"Wolkove","year":"2009","journal-title":"Can. Respir. J."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0655","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2125.2008.03177.x","article-title":"Amiodarone-induced pulmonary toxicity","volume":"66","author":"Ernawati","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104521_bib0660","first-page":"667","article-title":"Severe amiodarone induced pulmonary toxicity","volume":"4","author":"Nacca","year":"2012","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.phrs.2019.104521_bib0665","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4137\/CCRep.S39809","article-title":"Amiodarone-induced pulmonary toxicity - a frequently missed complication","volume":"9","author":"Sweidan","year":"2016","journal-title":"Clin. Med. Insights Case Rep."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0670","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0039-6257(97)00118-5","article-title":"Ocular side effects of amiodarone","volume":"42","author":"Mantyjarvi","year":"1998","journal-title":"Surv. Ophthalmol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104521_bib0675","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/01658107.2016.1247461","article-title":"Amiodarone-associated optic neuropathy: clinical review","volume":"41","author":"Wang","year":"2016","journal-title":"Neuroophthalmology"},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0680","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","article-title":"Drug-induced corneal epithelial changes","volume":"62","author":"Raizman","year":"2017","journal-title":"Surv. Ophthalmol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104521_bib0685","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.1982.01030030603011","article-title":"Amiodarone keratopathy: correlation to dosage and duration","volume":"100","author":"Kaplan","year":"1982","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.phrs.2019.104521_bib0690","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.12659\/MSM.890881","article-title":"Cutaneous adverse reactions of amiodarone","volume":"20","author":"Jaworski","year":"2014","journal-title":"Med. Sci. Monit."},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0695","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/clc.4960190713","article-title":"Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation","volume":"19","author":"Kounis","year":"1996","journal-title":"Clin. Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2019.104521_bib0700","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/archinte.160.12.1741","article-title":"Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology","volume":"160","author":"Goldschlager","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"12","key":"10.1016\/j.phrs.2019.104521_bib0705","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1365-4632.2008.03819.x","article-title":"Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas","volume":"48","author":"Maoz","year":"2009","journal-title":"Int. J. Dermatol."},{"issue":"7","key":"10.1016\/j.phrs.2019.104521_bib0710","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneurol.2009.96","article-title":"Frequency, characteristics, and risk factors for amiodarone neurotoxicity","volume":"66","author":"Orr","year":"2009","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0715","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.34.5.669","article-title":"Frequent neurologic toxicity associated with amiodarone therapy","volume":"34","author":"Charness","year":"1984","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.phrs.2019.104521_bib0720","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.410250618","article-title":"Parkinsonism and amiodarone therapy","volume":"25","author":"Werner","year":"1989","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104521_bib0725","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/ageing\/afn063","article-title":"Ataxia caused by amiodarone in older people","volume":"37","author":"Hindle","year":"2008","journal-title":"Age Ageing"},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0730","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/0735-1097(95)00591-9","article-title":"Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol","volume":"27","author":"Perry","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6 Pt 2","key":"10.1016\/j.phrs.2019.104521_bib0735","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/0002-8703(80)90214-8","article-title":"Amiodarone in the treatment of cardiac arrhythmias in children: one hundred thirty-five cases","volume":"100","author":"Coumel","year":"1980","journal-title":"Am. Heart J."},{"issue":"9","key":"10.1016\/j.phrs.2019.104521_bib0740","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/europace\/eut082","article-title":"Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement","volume":"15","author":"Brugada","year":"2013","journal-title":"Europace"},{"issue":"5","key":"10.1016\/j.phrs.2019.104521_bib0745","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/0735-1097(90)90251-J","article-title":"Long-term follow-up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects","volume":"15","author":"Guccione","year":"1990","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104521_bib0750","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02279881","article-title":"Effect on growth of children with cardiac dysrhythmias treated with amiodarone","volume":"9","author":"Ardura","year":"1988","journal-title":"Pediatr. Cardiol."},{"issue":"9244","key":"10.1016\/j.phrs.2019.104521_bib0755","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(00)03230-X","article-title":"Rhythm or rate control in atrial fibrillation--pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial","volume":"356","author":"Hohnloser","year":"2000","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.phrs.2019.104521_bib0760","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.0000012350.99718.AD","article-title":"Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT)","volume":"105","author":"Bansch","year":"2002","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.phrs.2019.104521_bib0765","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy","volume":"350","author":"Kadish","year":"2004","journal-title":"N. Engl. J. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181930430X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181930430X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:03:34Z","timestamp":1760911414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181930430X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":153,"alternative-id":["S104366181930430X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104521","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of amiodarone in contemporary management of complex cardiac arrhythmias","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104521"}}